Investor Overview

Overview

Tricida, Inc. , is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA’s Accelerated Approval Program.

Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

Report of unscheduled material events or corporate event

8-K View HTML

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A View HTML

Additional proxy soliciting materials - definitive

DEFA14A View HTML

An amendment to a SC 13D filing

SC 13D/A View HTML

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.